ClinicalTrials.gg
RecruitingNCT07674667FUNCtion ALSUpdated Oct 14, 2026

FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

A Phase 1/2 interventional study of TRCN-1023 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Trace Neuroscience, Inc.. Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Trace Neuroscience, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 14, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany — 17 open to participants now, 26 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · Germany.

Planned enrollment
58th of 63
30 · median 219
Started
2026
with 5 others
Phase 1/2
5 of 76
3 open now
Primary completion
2027-09
later than 13 of 25 live
Registered
75th of 76
by date

Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, this one is the 58th largest by planned enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 13 of the 25 other live ones, and was the 75th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

17 of the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, or all of them as a file.
02

Study summary

The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection). The trial will also assess how the body processes the drug and whether it shows early signs of benefit over 24 weeks.

Read the detailed description

TRCN-1023 is an investigational medicine designed to restore the function of a protein called UNC13A, which becomes disrupted in most people with Amyotrophic Lateral Sclerosis (ALS) due to a breakdown in how nerve cells process genetic information. This trial is designed to evaluate the safety and tolerability of TRCN-1023 given as a single injection into the fluid surrounding the spine, and to identify the best dose to carry forward into future studies. TRCN-1023 stays in the brain and spinal cord long enough that it may only need to be administered once every 24 weeks. The trial will also assess how the body processes the drug, whether it engages its intended target, and its effects on disease progression, physical function, and quality of life.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults aged 18 to 75 years
  • Diagnosis of ALS (clinically definite, clinically probable, or clinically probable laboratory supported)
  • ALS symptoms began within the past 24 months
  • Able to perform breathing tests: slow vital capacity (SVC) with consistent results, with breathing capacity of at least 60% of the expected value
  • Able and willing to meet all study requirements, including travel to the study site, brain magnetic resonance imaging (MRI) scans, lumbar punctures, and blood draws
  • Able and willing to use wearable sensors and complete speech assessments at home
  • On a stable dose of approved ALS medication for at least 4 weeks prior to screening
  • Capable of providing

Key Exclusion Criteria:

  • Carries a confirmed SOD1 or FUS gene mutation
  • Has a tracheostomy or requires continuous assisted ventilation more than 22 hours per day during the preceding 3 months before the first Screening Visit
  • Has a to brain MRI (e.g., pacemaker, metal implants)
  • Has a contraindication to lumbar puncture or spinal injection (e.g., blood clotting disorders, certain blood thinners, signs of increased pressure in the brain)
  • Has significant abnormal liver, kidney, or blood test results
  • Is currently enrolled in another clinical trial or has received an treatment within the past 4 weeks
  • Has previously received gene therapy, stem cell therapy, or another Antisense oligonucleotide (ASO) treatment
  • Has a condition other than ALS that could interfere with study participation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    TRCN-1023

    Antisense oligonucleotide (ASO) administered by intrathecal injection

    Drug: TRCN-1023

  • Placebo comparator
    Placebo

    Matching Placebo Comparator

    Other: Placebo

Interventions

  • DrugTRCN-1023

    TRCN-1023 administered as an intrathecal injection.

  • OtherPlacebo

    Intrathecal injection of artificial cerebrospinal fluid (aCSF).

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events

    Number and frequency of adverse events assessed over 24 weeks following a single intrathecal injection of TRCN-1023 or placebo

    Time frame: 24 Weeks

Secondary outcomes

  1. Plasma Concentration of TRCN-1023

    Plasma TRCN-1023 concentrations

    Time frame: Day 1 (pre-dose, 1, 2, 6, and 24 hours post-dose), Weeks 4, 10, 16, and 24

  2. Cerebrospinal Fluid (CSF) Concentration of TRCN-1023

    Cerebrospinal fluid (CSF) TRCN-1023 concentrations

    Time frame: Day 1 (pre-dose and 24 hours post-dose), Weeks 4, 16, and 24 (up to 4 lumbar punctures post-dose)

  3. Time to Peak Plasma Concentration (Tmax)

    Time of maximum observed plasma concentration (Tmax) of TRCN-1023

    Time frame: Day 1 (pre-dose, 1, 2, 6, and 24 hours post-dose), Weeks 4, 10, 16, and 24

  4. Peak Plasma Concentration (Cmax) of TRCN-1023

    Maximum observed plasma concentration (Cmax) of TRCN-1023

    Time frame: Day 1 (pre-dose, 1, 2, 6, and 24 hours post-dose), Weeks 4, 10, 16, and 24

  5. Area Under the Plasma Concentration-Time Curve to Last Measurable Concentration (AUClast) of TRCN-1023

    Area under the plasma concentration-time curve from time zero to last measurable concentration (AUClast) of TRCN-1023

    Time frame: Day 1 (pre-dose, 1, 2, 6, and 24 hours post-dose), Weeks 4, 10, 16, and 24

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.

Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2026
First posted
Jun 29, 2026
StartActual
Aug 20, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 Germany, 1 United Kingdom)
  • Universitätsklinikum Schleswig-Holstein · Lübeck, Germany
  • University College London · London, United Kingdom
Oct 14, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • University Medical Center Utrecht · Utrecht, NetherlandsContact person changed (no phone or email listed)
  • University of Sheffield · Sheffield, United KingdomContact person changed (no phone or email listed)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    2 sites added
    Show 2 added (1 Germany, 1 United Kingdom)
    • Universitätsklinikum Schleswig-Holstein · Lübeck, Germany
    • University College London · London, United Kingdom
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University Medical Center Utrecht · Utrecht, NetherlandsContact person changed (no phone or email listed)
    • University of Sheffield · Sheffield, United KingdomContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07674667
Lead sponsor
Trace Neuroscience, Inc.
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Aug 20, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Trace Neuroscience Clinical Trials
Contact
Clinicaltrials@traceneuro.com
+1 415-390-9509

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion